Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Frauenshuh Cancer Center | Researchclopedia

Back to institutions

Frauenshuh Cancer Center

Saint Louis Park, Minnesotahealthcare

40

Works

1,866

Citations

22

h-index

Top Research Topics

Vitamin D Research Studies Cancer survivorship and care Nutrition and Health in Aging

Top Researchers

Kim Robien Milken Institute

239 works14,166 citationsh-index: 61

Recent Research

567 XTX301, a tumor-activated Interleukin-12 (IL-12), demonstrated IL-12 pharmacology in patients with advanced solid tumors: pharmacodynamic data from first-in-human phase 1 study (NCT05684965)

Douglas R. Adkins,William H. Bradley,et al.

20250 citations

Estrogen and related hormone effects

Complementary and Alternative Medicine Studies

Cancer Genomics and Diagnostics

Cancer Immunotherapy and Biomarkers

Lymphoma Diagnosis and Treatment

Sarcoma Diagnosis and Treatment

Cannabis and Cannabinoid Research

Colorectal Cancer Treatments and Studies

Cholangiocarcinoma and Gallbladder Cancer Studies

Ronald E. Gordon Mayo Clinic

225 works12,303 citationsh-index: 57

Mary Jo Nissen University of Minnesota System

46 works7,860 citationsh-index: 27

Alice Shapiro University of Colorado Anschutz Medical Campus

80 works2,705 citationsh-index: 20

Karen K. Swenson

69 works2,534 citationsh-index: 29

Christina Wood Alliance for Clinical Trials in Oncology

69 works2,450 citationsh-index: 22

PATH-94. Use of tovorafenib for <i>BRAF</i> mutant or altered CNS tumors in adults: a single institution case series

Andrew E. Williams,Sydney Schultz,et al.

20250 citations

682 Ongoing phase 1/2 trial of the HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab: clinical safety update and renal cell carcinoma (RCC) efficacy analysis

David Sommerhalder,Kurt Demel,et al.

20240 citations

83 Tumor immune microenvironment characterization from pre- and post-dose tumors collected from a phase 1/2 study of NDI-101150, a hematopoietic progenitor kinase 1 (HPK1) inhibitor

Scott R. Daigle,GiNell Elliott,et al.

20240 citations

Phase 1/2 trial of the HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab: Clinical update.

Marcus Smith Noel,Kurt C. Demel,et al.

202410 citations

Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL

Mitchell R. Smith,Opeyemi A. Jegede,et al.

20248 citations